What Is Radiopharm Theranostics Limited (RADX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on Radiopharm Theranostics Limited at its current price of $4.29. The composite intrinsic value is estimated at $3.56 (-17.0% average return), with 7 models flagging overvaluation risk. The most optimistic model, First Chicago, places fair value at $6.49 (+51.3%), while Bayesian DCF — the most conservative — estimates $1.06 (-75.2%). This +126.5% gap reflects genuine analytical uncertainty about Radiopharm Theranostics Limited's intrinsic worth.
What Do the Models Say About RADX?
11 of 13 models are currently active for RADX. Of these, 4 models suggest upside while 7 models suggest overvaluation. The Bayesian DCF estimates RADX's intrinsic value at $1.06, implying -75.2% downside from the current price. See which stocks rank higher →
How Does RADX Rank in Pharmaceutical Preparations?
Among 438 Pharmaceutical Preparations stocks, RADX ranks #431 by Quality of Company score. CirclFi's QOC score of 2.0/10 evaluates 32 fundamental signals. A score of 2.0 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a pharmaceutical industry, Radiopharm Theranostics Limited operates in a sector where patent cliff exposure is a critical driver of valuation. Investors evaluating RADX should weigh these sector-specific dynamics alongside our model-derived fair values.
Is RADX a Value Trap?
The Value Trap algorithm is not active for RADX. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
11 of 13 models are active for Radiopharm Theranostics Limited. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Radiopharm Theranostics Limited's fundamental quality profile registers 2.0/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +126.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every RADX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across RADX's 11 active models, average confidence is 8%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad